title: Sipuleucel-T for the treatment of advanced prostate cancer.
abstract: Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response to prostate cancer that prolongs the overall survival of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC). The clinical development program and key efficacy, safety, and immune response findings from the phase III studies are presented. The integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer and future directions for research are discussed.
authors.affiliation: Dendreon Corp, Seattle, WA 98101, USA. mfrohlich@dendreon.com
authors.forename: Mark W
authors.initials: MW
authors.lastname: Frohlich
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology; D014020:Tissue Extracts / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T